-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44

Benzinga·07/13/2026 09:43:36
语音播报
Goldman Sachs analyst Kevin Strang initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating and announces Price Target of $44.